Top Markets
#1 Islamic Coin Islamic Coin +151.50%
#2 DOVU DOVU +48.64%
#3 Akedo Akedo +46.30%
#4 Black Phoenix Black Phoenix +34.55%
#5 Velvet Velvet +32.25%
#6 DoubleZero DoubleZero +19.36%
#7 Cross Cross +16.34%
#8 Cap Cap +15.21%
#9 Tutorial Tutorial +13.37%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.43%
Coin of the day
Islamic Coin Islamic Coin
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Pozycja w akcjach #39464
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Cena akcji
$0.11725176
Ostatnia synchronizacja: 2025-07-14
Kapitalizacja rynkowa
$481.50K
Zmiana (1 dzień)
-0.20%
Zmiana (1 rok)
0.00%
Kraj
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategoria

Healthcare
Zyski dla PHAXIAM Therapeutics S.A. (PHXM)
Zyski w Jun 2024 TTM: $-23.51M
Według najnowszych raportów finansowych PHAXIAM Therapeutics S.A., obecny zysk firmy wynosi $-23.51M. W roku 2022 firma osiągnęła zysk w wysokości $-1.28M, wzrost w porównaniu do zysku z roku 2021, który wynosił $-65.34M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy PHAXIAM Therapeutics S.A. od 2016 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE